# Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent

> **NCT01303692** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 312 (actual)

## Conditions studied

- GnRH Agonist Alone vs. GnRH Agonist Plus Anti-androgen Combination Treated Prostate Cancer Patients

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01303692
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 312 (ACTUAL)
- **Last updated:** 2015-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01303692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01303692, "Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01303692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*